Ixekizumab and Upadacitinib Combination Resolves Refractory Psoriatic Arthritis Symptoms in a 35-Year-Old Male
Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.
Abstract
Ixekizumab (IL-17 inhibitor) and upadacitinib (JAK inhibitor) combination resolved refractory psoriatic arthritis symptoms and normalized inflammatory markers in a 35-year-old male.
